Edward Tenthoff
Stock Analyst at Piper Sandler
(3.54)
# 861
Out of 5,241 analysts
198
Total ratings
43.98%
Success rate
6.7%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $8 → $16 | $7.67 | +108.60% | 3 | Apr 27, 2026 | |
| GENB Generate Biomedicines | Initiates: Overweight | $24 | $16.00 | +50.00% | 1 | Mar 24, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 → $110 | $48.41 | +127.23% | 8 | Mar 17, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $45 → $58 | $28.79 | +101.46% | 3 | Mar 13, 2026 | |
| IBRX ImmunityBio | Reiterates: Overweight | $7 → $12 | $7.97 | +50.56% | 1 | Mar 4, 2026 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $10 → $6 | $1.67 | +259.28% | 1 | Feb 25, 2026 | |
| ARVN Arvinas | Reiterates: Overweight | $16 → $20 | $9.08 | +120.26% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Overweight | $63 → $69 | $49.04 | +40.70% | 14 | Feb 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.34 | +70.94% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $18.15 | +103.86% | 4 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 → $110 | $76.67 | +43.47% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $1.77 | +351.98% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $98 → $125 | $82.21 | +52.05% | 5 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 → $23 | $6.69 | +243.80% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 → $6 | $1.30 | +361.54% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $449 → $489 | $286.98 | +70.40% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.31 | +178.42% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $9.74 | +54.00% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $38.97 | -48.68% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.35 | +418.52% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $17.29 | +177.62% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $14.99 | +60.11% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $27.55 | +183.12% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $11.22 | +167.38% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $1.83 | +3,451.91% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.81 | +2,358.21% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.10 | +172.73% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $90 | $23.01 | +291.13% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.76 | +241.88% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.51 | +232.23% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.94 | +2,184.26% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $7.64 | +2,256.02% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.39 | +153.02% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $4.45 | +731.46% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $4.69 | +249,927,405.33% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $799.32 | -55.71% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $436.95 | -26.08% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.28 | +143.19% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $50.13 | -28.19% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.42 | +1,660.56% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.56 | +26,637.97% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $698.25 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $21.71 | +4,800.97% | 2 | Apr 15, 2013 |
Karyopharm Therapeutics
Apr 27, 2026
Reiterates: Overweight
Price Target: $8 → $16
Current: $7.67
Upside: +108.60%
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $24
Current: $16.00
Upside: +50.00%
CRISPR Therapeutics AG
Mar 17, 2026
Reiterates: Overweight
Price Target: $105 → $110
Current: $48.41
Upside: +127.23%
Capricor Therapeutics
Mar 13, 2026
Reiterates: Overweight
Price Target: $45 → $58
Current: $28.79
Upside: +101.46%
ImmunityBio
Mar 4, 2026
Reiterates: Overweight
Price Target: $7 → $12
Current: $7.97
Upside: +50.56%
Cardiff Oncology
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $6
Current: $1.67
Upside: +259.28%
Arvinas
Feb 25, 2026
Reiterates: Overweight
Price Target: $16 → $20
Current: $9.08
Upside: +120.26%
Moderna
Feb 23, 2026
Maintains: Overweight
Price Target: $63 → $69
Current: $49.04
Upside: +40.70%
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.34
Upside: +70.94%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $18.15
Upside: +103.86%
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $76.67
Upside: +43.47%
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.77
Upside: +351.98%
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $82.21
Upside: +52.05%
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $6.69
Upside: +243.80%
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.30
Upside: +361.54%
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $286.98
Upside: +70.40%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.31
Upside: +178.42%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $9.74
Upside: +54.00%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $38.97
Upside: -48.68%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.35
Upside: +418.52%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $17.29
Upside: +177.62%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $14.99
Upside: +60.11%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $27.55
Upside: +183.12%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $11.22
Upside: +167.38%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $1.83
Upside: +3,451.91%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.81
Upside: +2,358.21%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.10
Upside: +172.73%
Jul 26, 2024
Maintains: Overweight
Price Target: $240 → $90
Current: $23.01
Upside: +291.13%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.76
Upside: +241.88%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.51
Upside: +232.23%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.94
Upside: +2,184.26%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $7.64
Upside: +2,256.02%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.39
Upside: +153.02%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $4.45
Upside: +731.46%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $4.69
Upside: +249,927,405.33%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $799.32
Upside: -55.71%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $436.95
Upside: -26.08%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.28
Upside: +143.19%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $50.13
Upside: -28.19%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.42
Upside: +1,660.56%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.56
Upside: +26,637.97%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $698.25
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $21.71
Upside: +4,800.97%